Treatment and prevention

According to the World Health Organization (WHO), 5–10% of adults and 20–30% of children suffer from influenza every year, while 250–500 thousand sick people die.

Influenza and ARVI viruses, penetrating into the organism rapidly propagate, causing the disease symptoms such as (fever, aches, headache, intoxication, cough, sore throat, runny nose). Often, acute respiratory viral infections and influenza can lead to the development of complications (bronchitis, pneumonia, otitis media, exacerbation of concomitant diseases, etc.).

ARBIDOL influences directly on the cause of the disease, i.e. on the ARVI and influenza viruses.

ARBIDOL can be used for treatment and prevention of influenza and ARVI in three modes.

cold anf flu

Treatment of influenza and various ARVI


Direct contact with the sick people suffering from the influenza and other ARVI


During the epidemic of influenza and other ARVI

ARBIDOL administration for treatment of influenza and ARVI contributes to:

  • reduction of
    disease severity
  • reduction of complication
    development risk
  • reduction of exacerbation of
    concomitant diseases
  • reduction of the of virus release
    period into the environment

Preventive administration of ARBIDOL allows reducing of diseases risk up to 7 times.

Important Safety Information

Active substances. Umifenovirum. АТC Code: J05AX13. INN: Umifenovirum. Pharmacotherapeutic group: antiviral agent. Pharmacodynamics. Arbidol is the antiviral medicinal product. It specifically inhibits in vitro viruses of influenza A and B and other viruses, i.e. agents of Acute Respiratory Virus Infections (ARVI). Based on its antiviral activity mechanism it belongs to the fusion inhibitors (fusions); it interacts with virus hemagglutinin. Contraindications. Hypersensitivity to Umifenovirum or any other component of the medicinal product; Paediatric patients under 2 years old. First trimester of pregnancy. Breast feeding period. Adverse reactions. Rare – allergic reactions.